Biologics License Application for Subcutaneous Formulation of “LEQEMBI(R)” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
TOKYO and CAMBRIDGE, Mass., Fe […]
TOKYO, Feb 9, 2026 – (JC […]
TOKYO//SINGAPORE, Feb 9, 2026 […]
All-new Versa Van TOKYO, Feb 6 […]
TOKYO and SHANGHAI, Feb 6, 202 […]
Shanghai, January 5, 2026 R […]
TOKYO, February 3,2026 – […]
KYOTO, Japan, Feb. 4, 2026 […]
KARIYA, JAPAN, Feb 3, 2026 […]
KAWASAKI, Japan, Feb 3, 2026 & […]